A Post-Marketing Surveillance Study on NesinaAct® Tablet Use Among Type 2 Diabetes Mellitus Participants in Korea

Takeda730 enrolled

Overview

The purpose of this post marketing surveillance (PMS) study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) and serious adverse drug reactions (SADRs) in participants who are treated for type 2 diabetes mellitus under NesinaAct® tablet therapy (alogliptin/pioglitazone) once daily by physicians in the real-world clinical practice setting over a period of 26 weeks.

The drug being tested in this survey is called NesinaAct® tablet. A surveillance is planned to examine safety and effectiveness of NesinaAct® tablet therapy in participants who are being treated for type 2 diabetes mellitus. The study will enroll approximately 730 patients. The study observes percentage of participants with adverse events (AEs) including serious adverse events (SAEs) and serious adverse drug reactions (SADRs) administered a dose of NesinaAct® tablet (alogliptin/pioglitazone) once daily as prescribed by the physician in routine practice over a period of 26 weeks. This multi-center trial is conducted in a total of 19 sites in Korea. The data is collected between October 2 2015 to August 30 2019 from the re-examination period up to 26 weeks.

Study Type

OBSERVATIONAL

Enrollment

730

Conditions

Type 2 Diabetes Mellitus

Interventions

NesinaAct® TabletDRUG

NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants inadequately controlled on diet and exercise. * Participants inadequately controlled on metformin alone. * Participants inadequately controlled on pioglitazone alone. * Participants inadequately controlled on metformin and pioglitazone combination therapy. * Participants switching from alogliptin co-administered with pioglitazone. Exclusion Criteria: * Participants treated with study drug outside of the locally approved label in Korea. * Participants with contraindication for the use of study drug (as described in the Korean product label).

Locations (8)

Unnamed facility

Busan, South Korea

Unnamed facility

Chuncheon, South Korea

Unnamed facility

Daejeon, South Korea

Unnamed facility

Gangneung-si, South Korea

Outcomes

Primary Outcomes

Percentage of Participants With Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs)

An SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Serious ADRs are defined as SAEs that are, in the investigator's opinion, of causal relationship to the study treatment. 95% Confidence Interval was calculated using exact method.

Time frame: First dose of surveillance drug treatment to within 30 days after the end of the treatment (up to 153 weeks)

Percentage of Participants With Unexpected Adverse Events (AEs) and Adverse Drug Reactions (ADRs) Not Mentioned in Precautions

An AE is any and all undesirable or unintended signs (including abnormal clinical laboratory values), symptoms, or disease that are incurred when the drug is administered, and is not related to causal relationship with the drug. An ADR is a harmful and unintended reaction resulting from usual administration and use of the drug, whose causal relationship with the drug cannot be excluded, and if causal relationship with the drug is unknown among AEs reported spontaneously, it is regarded as ADR. An unexpected ADR is an ADR with difference in the nature or severity, specificity, or the outcome, compared to the product licensure/notification of the drug. 95% Confidence Interval was calculated using exact method.

Time frame: First dose of surveillance drug treatment to within 30 days after the end of the treatment (up to 153 weeks)

Percentage of Participants With Expected/Already Known ADRs at Week 13

An ADR is a harmful and unintended reaction resulting from usual administration and use of the drug, whose causal relationship with the drug cannot be excluded, and if causal relationship with the drug is unknown among AEs reported spontaneously, it is regarded as ADR. Expected/already known ADRs are those listed in product licensure/notification of the drug. Data is reported as per duration of study drug treatment for this outcome measure from administration start date to AE onset date. 95% Confidence Interval was calculated using exact method.

Time frame: Week 13

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.